Nicolas Bazan

Last updated

Nicolas G. Bazan, neuroscientist, eye researcher, and author. His research focuses on neurodegenerative diseases, neuroinflammation (inflammation of nervous tissue), and cell survival using cellular, molecular, and disease models including lipidomics. He also operates "Nicholas Bazan Wines" with Mark Wahle.

Contents

Appointments

Early life and education

Nicolas G. Bazan was born in Los Sarmientos, Tucuman, Argentina on May 22, 1942. He received his MD from the University of Tucuman School of Medicine, Argentina (1965) and was a postdoctoral fellow at Columbia University's College of Physicians and Surgeons and Harvard Medical School (1965–1968). The research that he performed at Harvard was the basis for his Doctorate in Medical Sciences thesis (University of Tucuman, 1971). He became the founding director of the Louisiana State University Heath Sciences Center (LSUHSC) Neuroscience Center of Excellence in 1989.

Scientific contributions

Translational medicine and industry

Start-Up Companies

Patents

Other activities

Related Research Articles

<span class="mw-page-title-main">Arachidonic acid</span> Fatty acid used metabolically in many organisms

Arachidonic acid is a polyunsaturated omega-6 fatty acid 20:4(ω-6), or 20:4(5,8,11,14). If its precursors or diet contains linoleic acid it is formed by biosynthesis and can be deposited in animal fats. It is a precursor in the formation of leukotrienes, prostaglandins, and thromboxanes.

Phosphatidic acids are anionic phospholipids important to cell signaling and direct activation of lipid-gated ion channels. Hydrolysis of phosphatidic acid gives rise to one molecule each of glycerol and phosphoric acid and two molecules of fatty acids. They constitute about 0.25% of phospholipids in the bilayer.

Phospholipase A<sub>2</sub> Peripheral membrane protein

The enzyme phospholipase A2 (EC 3.1.1.4, PLA2, systematic name phosphatidylcholine 2-acylhydrolase) catalyses the cleavage of fatty acids in position 2 of phospholipids, hydrolyzing the bond between the second fatty acid “tail” and the glycerol molecule:

<span class="mw-page-title-main">Docosahexaenoic acid</span> Chemical compound

Docosahexaenoic acid (DHA) is an omega-3 fatty acid that is an important component of the human brain, cerebral cortex, skin, and retina. It is given the fatty acid notation 22:6(n-3). It can be synthesized from alpha-linolenic acid or obtained directly from maternal milk, fatty fish, fish oil, or algae oil. The consumption of DHA contributes to numerous physiological benefits, including cognition. As a component of neuronal membranes, the function of DHA is to support neuronal conduction and to allow the optimal functioning of neuronal membrane proteins.

Platelet-activating factor, also known as PAF, PAF-acether or AGEPC (acetyl-glyceryl-ether-phosphorylcholine), is a potent phospholipid activator and mediator of many leukocyte functions, platelet aggregation and degranulation, inflammation, and anaphylaxis. It is also involved in changes to vascular permeability, the oxidative burst, chemotaxis of leukocytes, as well as augmentation of arachidonic acid metabolism in phagocytes.

<span class="mw-page-title-main">Lipoxygenase</span>

Lipoxygenases (LOX) are a family of (non-heme) iron-containing enzymes, more specifically oxidative enzymes, most of which catalyze the dioxygenation of polyunsaturated fatty acids in lipids containing a cis,cis-1,4-pentadiene into cell signaling agents that serve diverse roles as autocrine signals that regulate the function of their parent cells, paracrine signals that regulate the function of nearby cells, and endocrine signals that regulate the function of distant cells.

<span class="mw-page-title-main">Lipid signaling</span> Biological signaling using lipid molecules

Lipid signaling, broadly defined, refers to any biological cell signaling event involving a lipid messenger that binds a protein target, such as a receptor, kinase or phosphatase, which in turn mediate the effects of these lipids on specific cellular responses. Lipid signaling is thought to be qualitatively different from other classical signaling paradigms because lipids can freely diffuse through membranes. One consequence of this is that lipid messengers cannot be stored in vesicles prior to release and so are often biosynthesized "on demand" at their intended site of action. As such, many lipid signaling molecules cannot circulate freely in solution but, rather, exist bound to special carrier proteins in serum.

<span class="mw-page-title-main">2-Arachidonoylglycerol</span> Chemical compound

2-Arachidonoylglycerol (2-AG) is an endocannabinoid, an endogenous agonist of the CB1 receptor and the primary endogenous ligand for the CB2 receptor. It is an ester formed from the omega-6 fatty acid arachidonic acid and glycerol. It is present at relatively high levels in the central nervous system, with cannabinoid neuromodulatory effects. It has been found in maternal bovine and human milk. The chemical was first described in 1994–1995, although it had been discovered some time before that. The activities of phospholipase C (PLC) and diacylglycerol lipase (DAGL) mediate its formation. 2-AG is synthesized from arachidonic acid-containing diacylglycerol (DAG).

Arachidonate 5-lipoxygenase, also known as ALOX5, 5-lipoxygenase, 5-LOX, or 5-LO, is a non-heme iron-containing enzyme that in humans is encoded by the ALOX5 gene. Arachidonate 5-lipoxygenase is a member of the lipoxygenase family of enzymes. It transforms essential fatty acids (EFA) substrates into leukotrienes as well as a wide range of other biologically active products. ALOX5 is a current target for pharmaceutical intervention in a number of diseases.

<span class="mw-page-title-main">Platelet-activating factor receptor</span> Protein-coding gene in the species Homo sapiens

The platelet-activating factor receptor(PAF-R) is a G-protein coupled receptor which binds platelet-activating factor. It is encoded in the human by the PTAFR gene.

<span class="mw-page-title-main">ALOX12</span> Protein-coding gene in the species Homo sapiens

ALOX12, also known as arachidonate 12-lipoxygenase, 12-lipoxygenase, 12S-Lipoxygenase, 12-LOX, and 12S-LOX is a lipoxygenase-type enzyme that in humans is encoded by the ALOX12 gene which is located along with other lipoyxgenases on chromosome 17p13.3. ALOX12 is 75 kilodalton protein composed of 663 amino acids.

<span class="mw-page-title-main">Phospholipase C</span> Class of enzymes

Phospholipase C (PLC) is a class of membrane-associated enzymes that cleave phospholipids just before the phosphate group (see figure). It is most commonly taken to be synonymous with the human forms of this enzyme, which play an important role in eukaryotic cell physiology, in particular signal transduction pathways. Phospholipase C's role in signal transduction is its cleavage of phosphatidylinositol 4,5-bisphosphate (PIP2) into diacyl glycerol (DAG) and inositol 1,4,5-trisphosphate (IP3), which serve as second messengers. Activators of each PLC vary, but typically include heterotrimeric G protein subunits, protein tyrosine kinases, small G proteins, Ca2+, and phospholipids.

<span class="mw-page-title-main">Lipase</span> Class of enzymes which cleave fats via hydrolysis

In biochemistry, lipase refers to a class of enzymes that catalyzes the hydrolysis of fats. Some lipases display broad substrate scope including esters of cholesterol, phospholipids, and of lipid-soluble vitamins and sphingomyelinases; however, these are usually treated separately from "conventional" lipases. Unlike esterases, which function in water, lipases "are activated only when adsorbed to an oil–water interface". Lipases perform essential roles in digestion, transport and processing of dietary lipids in most, if not all, organisms.

Proliferative vitreoretinopathy (PVR) is a disease that develops as a complication of rhegmatogenous retinal detachment. PVR occurs in about 8–10% of patients undergoing primary retinal detachment surgery and prevents the successful surgical repair of rhegmatogenous retinal detachment. PVR can be treated with surgery to reattach the detached retina but the visual outcome of the surgery is very poor. A number of studies have explored various possible adjunctive agents for the prevention and treatment of PVR, such as methotrexate, although none have yet been licensed for clinical use.

<span class="mw-page-title-main">Lysophosphatidylcholine</span> Class of compounds

Lysophosphatidylcholines, also called lysolecithins, are a class of chemical compounds which are derived from phosphatidylcholines.

<span class="mw-page-title-main">1-Lysophosphatidylcholine</span>

1-Lysophosphatidylcholines are a class of phospholipids that are intermediates in the metabolism of lipids. They result from the hydrolysis of an acyl group from the sn-1 position of phosphatidylcholine. They are also called 2-acyl-sn-glycero-3-phosphocholines. The synthesis of phosphatidylcholines with specific fatty acids occurs through the synthesis of 1-lysoPC. The formation of various other lipids generates 1-lysoPC as a by-product.

<span class="mw-page-title-main">Diglyceride</span> Type of fat derived from glycerol and two fatty acids

A diglyceride, or diacylglycerol (DAG), is a glyceride consisting of two fatty acid chains covalently bonded to a glycerol molecule through ester linkages. Two possible forms exist, 1,2-diacylglycerols and 1,3-diacylglycerols. Diglycerides are natural components of food fats, though minor in comparison to triglycerides. DAGs can act as surfactants and are commonly used as emulsifiers in processed foods. DAG-enriched oil has been investigated extensively as a fat substitute due to its ability to suppress the accumulation of body fat; with total annual sales of approximately USD 200 million in Japan since its introduction in the late 1990s till 2009.

Protectin D1 also known as neuroprotectin D1 and abbreviated most commonly as PD1 or NPD1 is a member of the class of specialized proresolving mediators. Like other members of this class of polyunsaturated fatty acid metabolites, it possesses strong anti-inflammatory, anti-apoptotic and neuroprotective activity. PD1 is an aliphatic acyclic alkene 22 carbons in length with two hydroxyl groups at the 10 and 17 carbon positions and one carboxylic acid group at the one carbon position.

Dihydroxy-E,Z,E-PUFA are metabolites of polyunsaturated fatty acids (PUFA) that possess two hydroxyl residues and three in series conjugated double bonds having the E,Z,E cis-trans configuration. These recently classified metabolites are distinguished from the many other dihydroxy-PUFA with three conjugated double bonds that do not have this critical E,Z,E configuration: they inhibit the function of platelets and therefore may be involved in controlling and prove useful for inhibiting human diseases which involve the pathological activation of these blood-borne elements.

<span class="mw-page-title-main">Reinforced lipids</span> Deuterated lipid molecules

Reinforced lipids are lipid molecules in which some of the fatty acids contain deuterium. They can be used for the protection of living cells by slowing the chain reaction due to isotope effect on lipid peroxidation. The lipid bilayer of the cell and organelle membranes contain polyunsaturated fatty acids (PUFA) are key components of cell and organelle membranes. Any process that either increases oxidation of PUFAs or hinders their ability to be replaced can lead to serious disease. Correspondingly, use of reinforced lipids that stop the chain reaction of lipid peroxidation has preventive and therapeutic potential.

References

  1. Bazan NG. Effects of ischemia and electroconvulsive shock on free fatty acid pool in the brain. Biochim Biophys Acta 218:1-10, 1970
  2. Bazan NG: Changes in free fatty acids of brain by drug induced convulsions, electroshock and anesthesia. J Neurochem 18:1379-1385, 1971
  3. Horrocks LA, Farooqui AA. NMDA receptor-stimulated release of arachidonic acid: Mechanisms for the Bazan Effect. In Cell Signal Transduction, Second Messengers, and Protein Phosphorylation in Health and Disease, AM Municio, MT Miras-Portugal (eds), Plenum Press, New York, pgs 113-128, 1994
  4. Sun GY, Xu J, Jensen MD, Simonyi A: Phospholipase A2 in central nervous system: Implications for neurodegeneration diseases. J Lipid Res 45:205-213, 2004
  5. Aveldano MI, Bazan NG. High content of docosahexaenoate and of total diacylglycerol in retina. Biochem Biophys Res Comm 48:689-693, 1972.
  6. Aveldano MI, Bazan NG. Fatty acid composition and level of diacylglycerols and phosphoglycerides in brain and retina. Biochim Biophys Aca 296:1-9, 1973
  7. Aveldano de Caldironi MI, Bazan NG: Composition and biosynthesis of molecular species of retina phosphoglycerides. Neurochem Internat 1:381-392, 1980
  8. Aveldano MI, Bazan NG: Molecular species of phosphatidylcholine, ethanolamine, serine and inositol in microsomal and photoreceptor membranes of bovine retina. J Lipid Res 24:620-627, 1983
  9. Aveldano MI, Pasquare de Garcia SJ, Bazan NG: Biosynthesis of molecular species of inositol, choline, serine, and ethanolamine glycerophospholipids in the bovine retina. J Lipid Res 24:628-638, 1983
  10. Aveldano MI, Bazan NG: Differential lipid deacylation during brain ischemia in a homeotherm and a poikilotherm. Content and composition of free fatty acids and triacylglycerols. Brain Res 100:99-110, 1975
  11. Aveldano MI, Bazan NG: Rapid production of diacylglycerols enriched in arachidonate and stearate during early brain ischemia. J Neurochem 25:919-920, 1975
  12. Aveldano de Caldironi MI, Bazan NG. Acyl groups, molecular species and labeling by 14C-glycerol and 3H-arachidonic acid of vertebrate retina glycerolipids. In Advances in Experimental Medicine and Biology, Fucntino and Biosynthesis of Lipids, Vol 83, NG Bazan, RR Brenner, NM Giusto (esd), Plenum Press, New York, pgs 397-404, 1997.
  13. Rodriguez de Turco EB, Morelli de Liberti S, Bazan NG: Stimulation of free fatty acid and diacylglycerol accumulation in cerebrum and cerebellum during bicuculline induced status epilepticus. Effect of pretreatment with alpha methyl p tyrosine and p chlorophenyl¬alamine. J Neurochem 40:252-259, 1983
  14. Van Rooijen LAA, Vadnal R, Dobard P, Bazan NG: Enhanced inositide turnover in brain during bicuculline induced status epilepticus. Biochim Biophys Res Comm 136:827-834, 1986
  15. Vadnal RE, Bazan NG: Electroconvulsive shock stimulates polyphosphoinositide degradation and inositol trisphosphate accumulation in rat cerebrum: Lithium pretreatment does not potentiate these changes. Neurosci Lett 80:75-79, 1987
  16. Reddy TS, Bazan NG: Arachidonic acid, stearic acid and diacylglycerol accumulation correlates with the loss of phosphatidylinositol 4,5 bisphosphate in cerebrum 2 seconds after electroconvulsive shock. Complete reversion of changes 5 minutes after stimulation. J Neurosci Res 18:449-455, 1987
  17. Vadnal RE, Bazan NG: Carbamazepine inhibits the electroconvulsive shock induced [H] IP3 accumulation in rat cerebral cortex and hippocampus. Biochem Biophys Res Comm 153:128-134, 1988
  18. Katsura K, Rodriguez de Turco EB, Folbergrová J, Bazan NG, Siesjö: The coupling among energy failure, loss of ion homeostasis, and lipolysis during ischemia. J Neurochem 61:1677-1684, 1993
  19. Bazan NG, Allan G, Rodriguez de Turco EB: Role of phospholipase A2 and membrane-derived lipid second messengers in excitable membrane function and transcriptional activation of genes. Implications in cerebral ischemia. Prog in Brain Res 96:247-257, 1993
  20. Giusto NM, Bazan NG: Phosphatidic acid of retinal microsomes contains a high proportion of docosahexaenoate. Biochem Biophys Res Comm 91:791-794, 1979
  21. Bazan NG, di Fazio de Escalante MS, Careaga MM, Bazan HEP, Giusto NM: High content of 22:6 (docosahexaenoate) and active [2-3H]glycerol metabolism of phosphatidic acid from photoreceptor membranes. Biochim Biophys Acta 712:702-706, 1982
  22. Bazan HEP, Careaga MM, Sprecher H, Bazan NG: Chain elongation and desaturation of eicosapentaenoate to docosahexaenoate and phospholipid labeling in the rat retina in vivo. Biochim Biophys Acta 712:123-128, 1982
  23. Bazan HEP, Sprecher H, Bazan NG: De novo biosynthesis of docosahexaenoyl phosphatidic acid in bovine retinal microsomes. Biochim Biophys Acta 796:11-19, 1984
  24. Reddy TS, Bazan NG: Kinetic properties of arachidonoyl coenzyme A synthetase in rat brain microsomes. Arch Biochem Biophys 226:125-133, 1983
  25. Reddy TS, Sprecher H, Bazan NG: Long chain acyl coenzyme A synthetase from rat brain microsomes: Kinetic studies using [1-14C]docosahexaenoic acid substrate. Eur J Biochem 145:21-29, 1984
  26. Birkle DL, Bazan NG: Lipoxygenase and cyclooxygenase reaction products and incorporation into glycerolipids of radiolabeled arachidonic acid in the bovine retina. Prostaglandins 27:203-216, 1984
  27. Birkle DL, Bazan NG: Effects of K+ depolarization on the synthesis of prostaglandins and hydroxyeicosatetra(5,8,11,14)enoic acids (HETE) in the rat retina. Evidence for esterification of 12 HETE in lipids. Biochim Biophys Acta 795:564-573, 1984
  28. Bazan NG, Birkle DL, Reddy TS: Docosahexaenoic acid (22:6, n 3) is metabolized to lipoxygenase reaction products in the retina. Biochem Biophys Res Comm 125:741-747, 1984
  29. 1 2 Beuckmann CT, Gordon WC, Kanaoka Y, Eguchi N, Marcheselli VL, Gerashchenko DY, Urade Y, Hayaishi O, Bazan NG: Lipocalin-type prostaglandin D synthase (β-trace) is located in pigment epithelial cells of rat retina and accumulates within interphotoreceptor matrix. J Neurosci 16:6119-6124, 1996
  30. Bazan NG, Reddy TS, Redmond TM, Wiggert B, Chader GJ: Endogenous fatty acids are covalently and non covalently bound to interphotoreceptor retinoid binding protein in the monkey retina. J Biol Chem 260:13677-13680, 1985
  31. Scott BL, Reddy TS, Bazan NG: Docosahexaenoate metabolism and fatty acid composition in developing retinas of normal and rd mutant mice. Exp Eye Res 44:101-113, 1987
  32. Scott BL, Racz E, Lolley RN, Bazan NG: Developing rod photoreceptors from normal and mutant rd mouse retinas: Altered fatty acid composition early in development of the mutant. J Neurosci Res 20:202 211, 1988
  33. Scott BL, Bazan NG: Membrane docosahexanoate is supplied to the developing brain and retina by the liver. Proc Natl Acad Sci USA 86:2903 2907, 1989
  34. Gordon WC, Bazan NG: Docosahexaenoic acid utilization during rod photoreceptor cell renewal. J Neurosci 10:2190-2204, 1990
  35. Rodriguez de Turco, EB, Gordon WC, Bazan NG: Rapid and selective uptake, metabolism, and cellular distribution of docosahexaenoic acid among rod and cone photoreceptor cells in the frog retina. J Neurosci 11:3667-3678, 1991
  36. Martin RE, Bazan NG: Changing fatty acid content of growth cone lipids prior to synaptogensis. J. Neurochem 59:318-325, 1992
  37. Gordon WC, Rodriguez de Turco EB, Bazan NG:Retinal pigment epithelial cells play a central role in the conservation of docosahexaenoic acid by photoreceptor cells after shedding and phagocytosis. Curr Eye Res 11:73-83, 1992
  38. Gordon WC, Bazan NG: Visualization of [3H]docosahexaenoic acid trafficking through photoreceptors and retinal pigment epithelium by electron microscope autoradiography. Invest Ophthalmol Vis Sci 34:2402-2411, 1993
  39. Bazan NG, Rodriguez de Turco EB, Gordon WC: Pathways for the uptake and conservation of docosahexaenoic acid in photoreceptors and synapses: Biochemical and autoradiographic analysis. Can J Physiol Pharmacol 71(9):690-698, 1993
  40. Bazan NG, Scott BL, Reddy TS, Pelias MZ: Decreased content of docosahexanoate and arachidonate in plasma phospholipids in Usher's syndrome. Biochem Biophys Res Commun 141:600-604, 1986
  41. Ershov AV, Lukiw WJ, Bazan NG: Selective transcription factor induction in retinal pigment epithelial cells during photoreceptor phagocytosis. J Biol Chem 271:28458-28462, 1996
  42. Gerashchenko DY, Beuckmann CT, Marcheselli VL, Gordon WC, Kanaoka Y, Eguchi N, Urade Y, Hayaishi O, Bazan NG: Localization of lipocalin-type prostaglandin D synthase (β-trace) in iris, ciliary body, and eye fluids. Invest Ophthalmol Vis Sci 39:198-203, 1998
  43. Rodriguez de Turco EB, Deretic D, Bazan NG, Papermaster D: Post-golgi vesicles cotransport docosahexaenoyl-phospholipids and rhodopsin during frog photoreceptor membrane biogenesis. J Biol Chem 272:10491-10497, 1997
  44. Panetta T, Marcheselli VL, Braquet P, Spinnewyn B, Bazan NG: Effects of a platelet-activating factor antagonist (BN 52021) on free fatty acids, diacylglycerols, polyphospho¬inositides and blood now in the gerbil brain: Inhibition of ischemia re¬perfusion induced cerebral injury. Biochem Biophys Res Comm 149:580-587, 1987
  45. Marcheselli VL, Rossowska M, Domingo MT, Braquet P, Bazan NG: Distinct platelet-activating factor binding sites in synaptic endings and in intracellular membranes of rat cerebral cortex. J Biol Chem 265:9140-9145, 1990
  46. Squinto SP, Block AL, Braquet P, Bazan NG: Platelet-activating factor stimulates a Fos/Jun/AP-1 transcriptional signaling system in human neuroblastoma cells. J Neurosci Res 24:558-566, 1989
  47. Squinto SP, Braquet P, Block AL, Bazan NG: Platelet-activating factor activates HIV promoter in transfected SH-SY5Y neuroblastoma cells and MOLT-4 T lymphocytes. J Mol Neurosci 2:79-84, 1990
  48. Bazan NG, Squinto SP, Braquet P, Panetta T, Marcheselli VL: Platelet-activating factor and polyunsaturated fatty acids in cerebral ischemia or convulsions: Intracellular PAF-binding sites and activation of a Fos/Jun/Ap-1 transcriptional signaling system. Lipids 26:1236-1242, 1991
  49. Marcheselli VL, and Bazan NG: Platelet-activating factor is a messenger in the electroconvulsive shock-induced transcriptional activation of c-fos and zif-268 in hippocampus. J Neurosci Res 37:54-61, 1994
  50. Clark GD, Happel LT, Zorumski CF, Bazan NG: Enhancement of hippocampal excitatory synaptic transmission by platelet-activating factor. Neuron 9:1211-1216, 1992
  51. Kato K, Clark GD, Bazan NG, Zorumski CF: Platelet activating factor as a potential retrograde messenger in Ca1 hippocampal long-term potentiation. Nature 367:175-179, 1994
  52. Izquierdo I, Fin C, Schmitz PK, Da Silva RC, Jerusalinsky D, Quillfeldt JA, Ferreira MBG, Medina JH, Bazan NG: Memory enhancement by intrahippocampal, intraamygdala, or intraentorhinal infusion of platelet-activating factor measured in an inhibitory avoidance task. Proc Natl Acad Sci 92:5047-5051, 1995
  53. Packard MG, Teather L, Bazan NG: Effect of intra-caudate nucleus injections of platelet-activating factor and the PAF antagonist BN 52021 on memory. Neurobiol Learn Mem 66:177-182, 1996
  54. Bazan NG, Fletcher BS, Herschman HR, Mukherjee PK: Platelet-activating factor and retinoic acid synergistically activate the inducible prostaglandin synthase gene. Proc Natl Acad Sci 91:5252-5256, 1994
  55. Marcheselli VL, Bazan NG: Sustained induction of prostaglandin endoperoxide synthase-2 by seizures in hippocampus: Inhibition by a platelet-activating factor antagonist. J Biol Chem 271:24794-24799, 1996
  56. Kolko M, DeCoster MA, Rodriguez de Turco EB, Bazan NG: Synergy by secretory phospholipase A2 and glutamate on inducing cell death and sustained arachidonic acid metabolic changes in primary cortical neuronal cultures. J Biol Chem 271:32722-32728, 1996
  57. Kolko M, Bruhn T, Christensen T, Lazdunski M, Lambeau G, Bazan NG, Diemer NH: Secretory phospholipase A2 potentiates glutamate-induced rat striatal neuronal cell death in vivo. Neurosci Letters 274:167-170, 1999
  58. Rodriguez de Turco EB, Jackson FR, DeCoster MA, Kolko M, Bazan NG: Glutamate signaling and secretory phospholipase A2 modulate the release of arachidonic acid from neuronal membrane. J Neurosi Res 68:558-567, 2002
  59. Rodriguez de Turco EB, Tang W, Tophan MK, Sakane F, Marcheselli VL, Chen C, Taketomi A, Prescott SM, Bazan NG: Diacylglycerol kinase ε regulates seizure susceptibility and long-term potentiation through arachidonoyl-inositol lipid signaling. Pro Natl Acad Sci 98:4740-4745, 2001
  60. Gordon WC, Casey DM, Lukiw WJ, Bazan NG: DNA damage and repair in light-induced photoreceptor degeneration. Invest Ophthalmol Vis Sci 43:3511-3521, 2002
  61. Lukiw WJ, Gordon WC, Rogaev EI, Thompson H, Bazan NG: Presenilin-2 (PS2) expression up-regulation in a model of retinopathy of prematurity and pathoangiogensis. NeuroReport 12:53-57, 2001
  62. Bazan NG, Birkle DL, Reddy TS: Docosahexaenoic acid (22:6, n 3) is metabolized to lipoxygenase reaction products in the retina. Biochem Biophys Res Commun 125:741-747, 1984
  63. Marcheselli VL, Hong S, Lukiw WJ, Tian XH, Gronert K, Musto A, Hardy M, Gimenez JM, Chiang N, Serhan CN, Bazan NG: Novel docosanoids inhibit brain ischema-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. J Biol Chem 278:43807-43817, 2003
  64. Belayev L, Marcheselli VL, Khoutorova L, Rodriguez de Turco EB, Busto R, Ginsberg MD, Bazan NG: Docosahexaenoic acid complexed to albumin elicits high-grade ischemic neuroprotection. Stroke 36:118-23, 2004
  65. Mukherjee PK, Marcheselli VL, Serhan CN, Bazan NG: Neuroprotectin D1: A docosahexanoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proc Natl Acad Sci, USA 101:8491-8496, 2004
  66. Lukiw WJ, Cui JG, Marcheselli VL, Bodker M, Botkjaer A, Gotlinger K, Serhan CN, Bazan NG: A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J Clin Invest 115:2774-2783, 2005
  67. Mukherjee PK, Marcheselli VL, Barreiro S, Hu J, Bok D, Bazan NG: Neurotrophins enhance retinal pigment epithelial cell survival through neuroprotectin D1 signaling. Proc Natl Acad Sci USA 104:13152-13157, 2007
  68. Mukherjee PK, Marcheselli VL, de Rivero Vaccari JC, Gordon WC, Jackson F, Bazan NG: Photoreceptor outer segment phagocytosis attenuates oxidative stress-induced apoptosis with concomitant neuroprotectin D1 synthesis. Proc Natl Acad Sci USA 104:13158-13163, 2007
  69. Bazan NG: Homeostatic regulation of photoreceptor cell integrity: significance of the potent mediator neuroprotectin D1 biosynthesized from docosahexaenoic acid: the Proctor Lecture. Invest Ophthalmol Vis Sci. 48:4866-4881, 2007
  70. Musto AE, Gjorstrup P, Bazan NG: The omega-3 fatty acid-derived neuroprotectin D1 limits hippocampal hyperexcitability and seizure susceptibility in kindling epileptogenesis. Epilepsia 52(9):1601-8, 2011
  71. "Retina protein that may help conquer blindness discovered".
  72. Rice DS, Calandria JM, Gordon WC, Jun B, Zhou Y, Gelfman CM, Li S, Jin M, Knott EJ, Chang B, Abuin A, Issa T, Potter D, Platt KA, Bazan NG: Adiponectin receptor 1 conserves docosahexaenoic acid and promotes photoreceptor cell survival. Nat Commun. 2015;6:6228
  73. "LSU Health New Orleans Makes Discovery Key to Preventing Blindness and Stroke Devastation".
  74. Calandria JM, Asatryan A, Balaszczuk V, Knott EJ, Jun BK, Mukherjee PK, Belayev L, Bazan NG: NPD1-mediated stereoselective regulation of BIRC3 expression through cREL is decisive for neural cell survival.Cell Death Differ. 2015;22:1363-77
  75. Musto AE, Rosencrans RF, Walker CP, Bhattacharjee S, Raulji CM, Belayev L, Fang Z, Gordon WC, Bazan NG: Dysfunctional epileptic neuronal circuits and dysmorphic dendritic spines are mitigated by platelet-activating factor receptor antagonism.Sci Rep. 2016;6:30298
  76. Anderson, Brett. "A new line of wine with New Orleans roots". Times-Picayune. Retrieved 27 July 2012.
  77. "Una Vida" website